See more : Mawana Sugars Limited (MAWANASUG.BO) Income Statement Analysis – Financial Results
Complete financial analysis of 4basebio PLC (4BB.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 4basebio PLC, a leading company in the Biotechnology industry within the Healthcare sector.
- Abivax SA American Depositary Shares (ABVX) Income Statement Analysis – Financial Results
- Golden Resources Development International Limited (0677.HK) Income Statement Analysis – Financial Results
- Wangfujing Group Co., Ltd. (600859.SS) Income Statement Analysis – Financial Results
- Varonis Systems, Inc. (VRNS) Income Statement Analysis – Financial Results
- LiqTech International, Inc. (LIQT) Income Statement Analysis – Financial Results
4basebio PLC (4BB.L)
About 4basebio PLC
4basebio PLC engages in the design, development, manufacturing, and supply of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company provides research kits, bulk enzymes, and other products, as well as licensing services; and AVV manufacturing services. It serves biotech, pharma, and contract development and manufacturing organization customers. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was incorporated in 2020 and is based in Cambridge, United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 506.00K | 268.00K | 338.00K | 462.00K | 202.00K |
| Cost of Revenue | 166.00K | 29.00K | 69.00K | 188.00K | 230.00K |
| Gross Profit | 340.00K | 239.00K | 269.00K | 274.00K | -28.00K |
| Gross Profit Ratio | 67.19% | 89.18% | 79.59% | 59.31% | -13.86% |
| Research & Development | 3.56M | 2.08M | 1.62M | 343.00K | 241.00K |
| General & Administrative | 1.26M | 2.71M | 1.73M | 516.00K | 95.00K |
| Selling & Marketing | 280.00K | 245.00K | 132.00K | 141.00K | 18.00K |
| SG&A | 1.54M | 2.96M | 1.86M | 657.00K | 113.00K |
| Other Expenses | 3.29M | 1.04M | 317.00K | -104.00K | 38.00K |
| Operating Expenses | 8.39M | 6.08M | 3.80M | 896.00K | 392.00K |
| Cost & Expenses | 8.56M | 6.11M | 3.87M | 1.08M | 622.00K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 302.00K | 89.00K | 113.00K | 94.00K | 109.00K |
| Depreciation & Amortization | 709.00K | 431.00K | 320.00K | 276.00K | 284.00K |
| EBITDA | -7.34M | -5.41M | -3.21M | -346.00K | -136.00K |
| EBITDA Ratio | -1,451.19% | -2,018.28% | -948.82% | -74.68% | -83.66% |
| Operating Income | -8.05M | -5.84M | -3.53M | -622.00K | -420.00K |
| Operating Income Ratio | -1,591.30% | -2,179.10% | -1,043.49% | -134.63% | -207.92% |
| Total Other Income/Expenses | -302.00K | -89.00K | -113.00K | -94.00K | 108.00K |
| Income Before Tax | -8.35M | -5.93M | -3.64M | -716.00K | -529.00K |
| Income Before Tax Ratio | -1,650.99% | -2,212.31% | -1,076.92% | -154.98% | -261.88% |
| Income Tax Expense | -689.00K | -779.00K | -405.00K | 3.00K | -106.00K |
| Net Income | -7.67M | -5.15M | -3.24M | -719.00K | -423.00K |
| Net Income Ratio | -1,514.82% | -1,921.64% | -957.10% | -155.63% | -209.41% |
| EPS | -0.62 | -0.42 | -0.26 | -0.06 | -0.03 |
| EPS Diluted | -0.62 | -0.42 | -0.26 | -0.06 | -0.03 |
| Weighted Avg Shares Out | 12.32M | 12.32M | 12.32M | 12.32M | 12.32M |
| Weighted Avg Shares Out (Dil) | 12.32M | 12.32M | 12.32M | 12.32M | 12.32M |
Source: https://incomestatements.info
Category: Stock Reports